CD8+CD103+ Tregs Attenuate Dry Eye Disease Through Suppression of CD4+ T Cell-Mediated Inflammation and Protection of Ocular Surface Integrity in Mice

Summary

Here, we present a protocol demonstrating the adoptive transfer of CD8+CD103+ regulatory T cells as an immunotherapeutic intervention to ameliorate desiccating stress-induced dry eye disease through the comprehensive modulation of pathogenic CD4+ T cell responses.

Abstract

CD8+CD103+ regulatory T cells represent a specialized immunosuppressive population with demonstrated therapeutic potential in autoimmune disorders; however, their role in ocular surface inflammation remains unexplored. This protocol describes a systematic approach for isolating CD8+CD103+ T cells from mice exposed to desiccating stress and evaluating their therapeutic efficacy through adoptive transfer in experimental dry eye disease. The methodology encompasses magnetic-activated cell sorting for CD8+CD103+ T-cell purification, standardized desiccating stress induction, and comprehensive functional assessments, including tear production measurement, corneal barrier permeability testing, and molecular analysis of inflammatory mediators. Representative results demonstrate that CD8+CD103+ T cell therapy significantly restored tear production, preserved conjunctival goblet cell populations, and maintained corneal epithelial barrier integrity. Treatment achieved substantial suppression of matrix metalloproteinase expression, reduced apoptotic cell death, and modulated cytokine profiles from pro-inflammatory to tissue-protective patterns. The protocol effectively reduced CD4+ T cell infiltration in ocular tissues, while simultaneously suppressing pathogenic IL-17A and IFN-γ production and enhancing protective IL-13 levels. This approach provides a robust experimental framework for investigating CD8+CD103+ T cell-mediated immunomodulation in ocular surface disorders and establishes a foundational methodology for developing novel cell-based therapeutics for dry eye disease management.

Introduction

Dry eye disease (DED) represents a prevalent and debilitating ocular surface disorder that has emerged as a significant global health concern, affecting 10-30% of the worldwide population and substantially compromising patients' quality of life, work productivity, and psychological well-being^1,2,3. The pathophysiology of DED involves a complex interplay between tear film instability, ocular surface inflammation, and neurosensory abnormalities, which collectively perpetuate a vicious cycle of tissue damage and functional impairment⁴. At the molecula....

Protocol

All experimental procedures involving animals were conducted in strict accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Experimental Animal Ethics Committee of the Jinan Second People's Hospital. All efforts were made to minimize animal suffering and reduce the number of animals used in accordance with the 3Rs principle (Replacement, Reduction, and Refinement).

1. Animal preparation and experimental design

1. Obtain female C57BL/6 mice aged 6-8 weeks from an approved laboratory animal facility (strain code: 027) with a specific pathogen-free health status.
....

Results

The successful implementation of this protocol yields comprehensive amelioration of desiccating stress-induced ocular surface pathology through CD8+CD103+ T cell-mediated immunomodulation. Positive results demonstrate significant restoration of tear production, typically achieving 60-80% recovery compared to non-stressed controls, while vehicle-treated animals exhibit persistent lacrimation deficits (Figure 1A).

Discussion

This investigation establishes CD8+CD103+ regulatory T cells as potent therapeutic agents desiccating stress-induced dry eye disease through comprehensive modulation of CD4+ T cell-mediated pathogenic responses. The findings reveal that adoptive transfer of CD8+CD103+ T cells achieves multifaceted protection of ocular surface integrity, encompassing functional restoration of tear production, preservation of mucosal architecture, maintenance of epithelial barrier function, and suppression of inflammatory tissue damage.

Materials

List of materials used in this article

Name	Company	Catalog Number	Comments
Anti-CD103-APC antibody	Biolegend	Clone 2E7	Flow cytometry and cell sorting
Anti-CD8 magnetic microbeads	Miltenyi Biotec	-	Magnetic cell separation
Corneal Oregon green-dextran	Invitrogen	D7172	Molecular weight 70,000
ELISA kit IFN-γ	eBioscience	BMS606	Cytokine quantification
ELISA kit IL-13	eBioscience	BMS6015	Cytokine quantification
ELISA kit IL-17A	eBioscience	BMS6001	Cytokine quantification
ImageJ	National Institutes of Health	version 1.53k
Phenol red cotton threads	Zone-Quick, Yokota	-	Tear production measurement
Scopolamine hydrobromide	Melonepharma	MB5860	Muscarinic antagonist